Transient Tachypnea of the Newborn Clinical Trial
Official title:
A Randomized Controlled Trial of Fluid Management in Transient Tachypnea of the Newborn
Transient tachypnea of the newborn (TTN) is a diagnosis given to infants born between 34 and
42 weeks gestation who develop difficulty breathing during the first days of life when no
specific cause of the breathing difficulty can be identified. Little is known about why some
babies develop TTN, and there have not been many formal studies of the best way to take care
of babies with this disease. Babies with TTN get better on their own within three to five
days after birth, but may require extra oxygen to breath well.
Most physicians believe that the symptoms of TTN are related to poor clearance of fluid from
the newborn's lungs. Babies with TTN have extra fluid visible on chest x-ray. Diuretics,
medicines that can help clear extra lung fluid in adults and in babies with extra lung fluid
for other reasons, do not to help babies with TTN. Babies with TTN need intravenous fluids
to be healthy because they breathe too fast to be able to eat. Breastfed babies only get a
very small amount of fluid in the first few days of life, as it normally takes several days
for a new mother to begin producing breastmilk. No one has yet examined whether giving
babies with TTN an amount of fluid similar to the small amount they would receive if they
could breastfeed would help them recover from TTN faster.
In this study, the investigators compare whether giving newborns "standard" intravenous
fluid or amounts of intravenous fluid more close to what a breastfed baby would receive
speeds recovery in newborns with TTN.
Status | Completed |
Enrollment | 64 |
Est. completion date | September 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 24 Hours |
Eligibility |
Inclusion Criteria: 1. Gestational age at birth 34 and 42 weeks of gestation 2. Admission to the Mount Sinai NICU during the first 24 hours of life 3. Diagnosis during the first 24 hours of life of transient tachypnea of the newborn Exclusion criteria: 1. Gestational age at birth less than 34 weeks or greater than 42 weeks at birth 2. No diagnosis of TTN made in the first 24 hours of life 3. Additional infant diagnosis of major cardiac disease 4. Additional infant diagnosis of major pulmonary disease other than TTN 5. Additional infant diagnosis of meconium aspiration syndrome 6. Additional infant diagnosis of major congenital anomaly with potential to affect respiratory status in the neonatal period 7. Additional infant diagnosis of infectious disease process potentially affecting respiratory status in the neonatal period 8. Observation of thick meconium in the amniotic fluid at delivery. 9. Maternal diagnosis of chorioamnionitis or other infection of the uterus or fallopian tubes pre- or peri-partum. Criteria for removal from the study: (a) Additional infant diagnosis of major cardiac, pulmonary, or other disease process potentially affecting respiratory status in the neonatal period (i.e., infection, meconium aspiration, pneumothorax, congenital anomaly) present during the study period. (b) Positive test of infection (e.g. blood, CSF, or urine culture; viral DFA; microscopy) drawn from infant at any point during the study period. (c) Maternal diagnosis of chorioamnionitis or other infection of the uterus or fallopian tubes at any point during hospital stay. (d) Objective clinical signs of dehydration: (i) Newborn urine output less than 2 mL/kg/hr over a twelve hour period at any point during the study period. (ii) Newborn serum sodium less than 130 mEq/L or greater than 150 mEq/L at any point during the study period. (iii) Newborn weight loss >10% of birth weight at any point during the study period. (e) Newborn blood glucose by point-of-care testing of less than 40 mg/dL at any point during the study period. (f) Administration of exogenous surfactant at any point during the study period. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Mount Sinai School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai |
United States,
Adams JM, Moreno J, Reynolds K, Campbell DW IV, Smith EO, Weisman LE. Resource utilization among neonatologists in a university children's hospital. Pediatrics. 1997 Jun;99(6):E2. — View Citation
Avery ME, Gatewood OB, Brumley G. Transient tachypnea of newborn. Possible delayed resorption of fluid at birth. Am J Dis Child. 1966 Apr;111(4):380-5. — View Citation
Demissie K, Marcella SW, Breckenridge MB, Rhoads GG. Maternal asthma and transient tachypnea of the newborn. Pediatrics. 1998 Jul;102(1 Pt 1):84-90. — View Citation
Jain L, Dudell GG. Respiratory transition in infants delivered by cesarean section. Semin Perinatol. 2006 Oct;30(5):296-304. Review. — View Citation
Jain L, Eaton DC. Physiology of fetal lung fluid clearance and the effect of labor. Semin Perinatol. 2006 Feb;30(1):34-43. Review. — View Citation
Lewis V, Whitelaw A. Furosemide for transient tachypnea of the newborn. Cochrane Database Syst Rev. 2002;(1):CD003064. Review. Update in: Cochrane Database Syst Rev. 2013;6:CD003064. — View Citation
Neville MC, Morton J. Physiology and endocrine changes underlying human lactogenesis II. J Nutr. 2001 Nov;131(11):3005S-8S. Review. — View Citation
Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care. 1998 Aug;21 Suppl 2:B79-84. Review. — View Citation
Riskin A, Abend-Weinger M, Riskin-Mashiah S, Kugelman A, Bader D. Cesarean section, gestational age, and transient tachypnea of the newborn: timing is the key. Am J Perinatol. 2005 Oct;22(7):377-82. — View Citation
Tutdibi E, Hospes B, Landmann E, Gortner L, Satar M, Yurdakök M, Dellagrammaticas H, Ors R, Ilikkan B, Ovali F, Sarman G, Kumral A, Arslanoglu S, Koc H, Yildiran A. Transient tachypnea of the newborn (TTN): a role for polymorphisms of surfactant protein B (SP-B) encoding gene? Klin Padiatr. 2003 Sep-Oct;215(5):248-52. — View Citation
Zanardo V, Simbi AK, Franzoi M, Soldà G, Salvadori A, Trevisanuto D. Neonatal respiratory morbidity risk and mode of delivery at term: influence of timing of elective caesarean delivery. Acta Paediatr. 2004 May;93(5):643-7. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of Respiratory Support | every hour until patient stable without respiratory support, an average of approximately 55 hours and a maximum of 205 hours | No | |
Secondary | Duration of ICU Admission | every day until discharge, an average of approximately 8 days and a maximum of 12 days | No | |
Secondary | Time to First Enteral Feed | hour until first enteral feed achieved, an average of approximately 40 hours and a maximum of 100 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01206946 -
Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants
|
Phase 2 | |
Completed |
NCT01310153 -
Effect of Supine or Prone Position After Caesarean Birth
|
N/A | |
Active, not recruiting |
NCT04780412 -
Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section
|
Phase 3 | |
Completed |
NCT01517958 -
Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates
|
N/A | |
Withdrawn |
NCT03499418 -
Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates
|
||
Completed |
NCT01859533 -
Positive End Expiratory Pressure With A T-piece Resuscitator For Near-Term and Term Infants With Respiratory Distress
|
Phase 2 | |
Completed |
NCT03208894 -
Role of Salbutamol and Furosemide in TTN
|
Phase 3 | |
Recruiting |
NCT01858129 -
Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
|
Phase 2 | |
Completed |
NCT01772381 -
Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean Section in Term Fetus
|
N/A | |
Recruiting |
NCT01270581 -
High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation
|
N/A | |
Recruiting |
NCT06278415 -
Physiologically Based Cord Clamping To Improve Neonatal Outcomes After Elective Cesarean Delivery
|
N/A | |
Not yet recruiting |
NCT06200519 -
Assessment of Diastolic Function During the Transitional Period and Infancy Using Serial Echocardiography
|
||
Completed |
NCT02965365 -
PATET Ratio to Rule Out Transient Tachypnea of the Newborn
|
N/A | |
Recruiting |
NCT05538780 -
Diagnosis of Transient Tachypnea of Newborn
|
||
Completed |
NCT04722016 -
LUNG ULTRASONOGRAPHY DECREASES RADIATION EXPOSURE
|
||
Recruiting |
NCT06270823 -
Reducing Respiratory Distress After Elective Caesarean Birth Through Knee-chest-flexion: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT03006354 -
nHFOV Versus nCPAP in Transient Tachypnea of the Newborn
|
N/A | |
Completed |
NCT05006235 -
Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn (TTN)
|
Phase 1 | |
Recruiting |
NCT03346343 -
Pulmonary Function Using Non-invasive Forced Oscillometry
|
N/A | |
Completed |
NCT03165305 -
The Role of Sustained Inflation on Short Term Respiratory Outcomes in Term Infants
|
N/A |